CSF2 and prostate carcinoma: Finally, efforts have been made to combine radiotherapy with vaccination against carcinoembryonic antigen (CEA) combined with GM-CSF in colorectal cancer (163), or against prostate specific antigen (PSA) combined with GM-CSF and IL-2 in patients with prostate cancer (164, 165).